Richard Meier Biography and Net Worth



Richard A. Meier is Chief Financial Officer & Executive Vice President at Intersect ENT, Inc.

He is also on the board of BioMarin Pharmaceutical, Inc. and Syntellix AG and Partner at Atlas Rock Co.

In his past career he held the position of CFO, Executive VP & President-International at Owens & Minor, Inc., Chief Financial Officer & Executive Vice President of Teleflex, Inc., President & Chief Operating Officer for Advanced Medical Optics, Inc., Chief Financial Officer & Executive Vice President of Valeant Pharmaceuticals International Corp., Principal at Greyhound Lines, Inc., Senior Vice President of Schroder & Co., Inc., Principal at Australian Capital Equity Pty Ltd., Principal at Manufacturers Hanover Corp. and Principal at Salomon Smith Barney, Inc.

Mr. Meier received an undergraduate degree from Princeton University.

What is Richard A. Meier's net worth?

The estimated net worth of Richard A. Meier is at least $9.08 million as of May 2nd, 2022. Mr. Meier owns 104,014 shares of BioMarin Pharmaceutical stock worth more than $9,084,583 as of March 29th. This net worth approximation does not reflect any other assets that Mr. Meier may own. Learn More about Richard A. Meier's net worth.

How do I contact Richard A. Meier?

The corporate mailing address for Mr. Meier and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected]. Learn More on Richard A. Meier's contact information.

Has Richard A. Meier been buying or selling shares of BioMarin Pharmaceutical?

Richard A. Meier has not been actively trading shares of BioMarin Pharmaceutical in the last ninety days. Most recently, Richard A. Meier sold 3,878 shares of the business's stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $82.09, for a transaction totalling $318,345.02. Following the completion of the sale, the director now directly owns 104,014 shares of the company's stock, valued at $8,538,509.26. Learn More on Richard A. Meier's trading history.

Who are BioMarin Pharmaceutical's active insiders?

BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Mark Alles (Director), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.

Are insiders buying or selling shares of BioMarin Pharmaceutical?

In the last twelve months, insiders at the biotechnology company sold shares 16 times. They sold a total of 180,605 shares worth more than $16,591,040.58. The most recent insider tranaction occured on March, 5th when insider Henry J Fuchs sold 35,341 shares worth more than $3,010,346.38. Insiders at BioMarin Pharmaceutical own 1.8% of the company. Learn More about insider trades at BioMarin Pharmaceutical.

Information on this page was last updated on 3/5/2024.

Richard A. Meier Insider Trading History at BioMarin Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/2/2022Sell3,878$82.09$318,345.02104,014View SEC Filing Icon  
5/6/2021Sell5,068$78.38$397,229.8499,340View SEC Filing Icon  
9/13/2018Sell3,000$99.24$297,720.0081,610View SEC Filing Icon  
8/27/2018Sell2,000$100.12$200,240.0069,610View SEC Filing Icon  
See Full Table

Richard A. Meier Buying and Selling Activity at BioMarin Pharmaceutical

This chart shows Richard A Meier's buying and selling at BioMarin Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $87.34
Low: $86.65
High: $88.66

50 Day Range

MA: $88.12
Low: $83.81
High: $94.04

2 Week Range

Now: $87.34
Low: $76.02
High: $100.38

Volume

1,027,708 shs

Average Volume

1,298,064 shs

Market Capitalization

$16.48 billion

P/E Ratio

99.25

Dividend Yield

N/A

Beta

0.31